文献速递肿瘤 PET/CT核素与放射性配体治疗

基于深度学习的放射性标记化合物-蛋白质相互作用预测用于靶向NDUFS1的放射性药物发现

Deep learning-based radiolabelled compound-protein interaction prediction for NDUFS1-targeting radiopharmaceutical discovery.
PubMed 文献 · EJNMMI Res · 2025-08-12

本研究开发了基于图神经网络和注意力机制的放射性药物-蛋白质相互作用预测模型,用于识别靶向线粒体核心亚基NDUFS1的显像候选物。模型经正常化合物-蛋白质对预训练后,用放射性药物-蛋白质对微调,五折交叉验证评估;微调模型优于仅用正常化合物训练的模型。BDBM210829被确定为靶向NDUFS1进行放射性标记的首选候选化合物。

要点

  • 构建了基于图神经网络和注意力机制的放射性药物-蛋白质相互作用预测模型。
  • 加入放射性特征的微调模型预测性能优于仅用正常化合物训练的模型。
  • BDBM210829被鉴定为靶向NDUFS1进行放射性标记的首选候选化合物。

核心结论

  • 本研究提出的基于深度学习的放射性标记化合物-蛋白质相互作用预测模型对放射性药物-蛋白质相互作用显示出良好预测性能。
  • BDBM210829被确定为靶向线粒体核心亚基NDUFS1进行放射性标记的首选候选化合物。
  • 该模型可作为放射性药物发现的有效虚拟筛选工具。

研究设计与样本

  • 本研究开发了基于图神经网络和注意力机制的放射性药物-蛋白质相互作用预测模型。
  • 模型先用正常化合物-蛋白质对预训练,再用放射性药物-蛋白质对数据集微调,并以五折交叉验证评估。

主要发现

  • 曲妥珠单抗、177Lu-DOTA-曲妥珠单抗和225Ac-DOTA-曲妥珠单抗的估计细胞活力值分别为290.1、89.01和8.262 nM。
  • 用正常化合物-蛋白质对训练的预测模型有效预测了结合亲和力。
  • 融入放射性特征的微调模型优于仅用正常化合物训练的同一模型。
  • 模型估计了化合物中与靶蛋白结合相关的重要子结构。
  • 鉴定出靶向NDUFS1蛋白的化合物,其中BDBM210829与NDUFS1结合时具有最佳结合亲和力、结合排名和LogP。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NDUFS1 is the largest subunit of OXPHOS complex I (MC-I) and mutations in this gene are associated with MC-I deficiency. This study aims to develop a graph neural network and attention mechanism-based radiopharmaceutical-protein (RP-protein) interaction prediction model for identifying an imaging candidate of mitochondrial function through targeting its core subunit NDUFS1. RESULTS: The estimated cell viability values for trastuzumab, 177Lu-DOTA-trastuzumab, and 225Ac-DOTA-trastuzumab were 290.1, 89.01, and 8.262 nM, respectively. The deep learning (DL) model was pretrained with normal compound-protein pairs. Afterwards, the model was fine-tuned with the dataset of RP-protein pairs and evaluated with five-fold cross validation. The prediction model trained with normal compound-protein pairs effectively predicted the binding affinity. The fine-tuned model incorporating radioactive properties outperformed the same model trained only on normal compounds. The model estimated the important substructure of a compound related to its binding to the target protein. NDUFS1 protein-targeting compounds were identified and BDBM210829 compound had the best binding affinities, binding rank, and LogP as it binds to the NDUFS1. CONCLUSIONS: This study proposed a DL-based radiolabelled compound-protein interaction prediction model to identify a radiopharmaceutical (RP) that binds to the mitochondrial core subunit NDUFS1. The proposed model shows good performance for predicting RP-protein interaction. BDBM210829 was identified as a top candidate for radiolabeling and targeting the mitochondrial core subunit NDUFS1. This model can be used as an effective virtual screening tool for RP discovery.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Almaslamani M, Yang J, Kang CS, et al. Deep learning-based radiolabelled compound-protein interaction prediction for NDUFS1-targeting radiopharmaceutical discovery. EJNMMI Res. 2025. PMID: 40794258. doi:10.1186/s13550-025-01300-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。